Sophia Eimermacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sophia Eimermacher has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Markus Pietsch
Technische Hochschule Köln, Fakultät für Angewandte Naturwissenschaften, Campusplatz 1, D-51379 Leverkusen, Germany
4 shared publications - Christian Werner
Institute of Biochemistry, Department of Chemistry and Biochemistry University of Cologne Koln Germany
2 shared publications - Dietmar Fischer
Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Zentrum für Pharmakologie, Institute I&II für Pharmakologie, Gleueler Straße 24, D-50931 Köln, Germany
2 shared publications - Karsten Niefind
Institute of Biochemistry, Department of Chemistry and Biochemistry University of Cologne Koln Germany
2 shared publications - Alfred Kick
Kurt-Schwabe-Institut für Mess- und Sensortechnik Meinsberg e.V., 04736 Waldheim, Germany
1 shared publication Alicia Porro-Pérez
Institute of General Organic Chemistry (CSIC), C/Juan de la Cierva 3, Madrid 28006, Spain
1 shared publication
Latest Publications
- Open Access
- 23 June 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (9) , 1730-1742
Discovery and characterization of a novel class of cyclic peptidic compounds inhibiting the subunit interaction of the protein kinase CK2α 2 β 2 holoenzyme
A high-throughput screening led to the discovery of cyclic pentapeptides binding to the CK2β-site of both CK2α and CK2α′. These compounds disturb the assembly of both CK2α 2 β 2 and CK2α′ 2 β 2 holoenzymes and induce holoenzyme dissociation.
- 23 June 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (9) , 1730-1742
Open AccessDiscovery and characterization of a novel class of cyclic peptidic compounds inhibiting the subunit interaction of the protein kinase CK2α 2 β 2 holoenzyme
A high-throughput screening led to the discovery of cyclic pentapeptides binding to the CK2β-site of both CK2α and CK2α′. These compounds disturb the assembly of both CK2α 2 β 2 and CK2α′ 2 β 2 holoenzymes and induce holoenzyme dissociation.
- Open Access
- 1 March 2025
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 406 (3-4) , 101-115
A CK2α′ mutant indicating why CK2α and CK2α′, the isoforms of the catalytic subunit of human protein kinase CK2, deviate in affinity to CK2β
Protein kinase CK2 (casein kinase 2) mainly exists as heterotetrameric holoenzyme with two catalytic subunits (CK2α or CK2α′) bound to a homodimer of non-catalytic subunits (CK2β). With CSNK2A1 and CSNK2A2, the human genome contains two paralogs encoding catalytic CK2 subunits. Both gene products, called CK2α and CK2α′, strongly interact with CK2β. An earlier report that CK2α′ has a lower CK2β affinity than CK2α is confirmed via isothermal titration calorimetry in this study. Furthermore, we show with a fluorescence-anisotropy assay that a CK2β-competitive peptide binds less strongly to CK2α′ than to CK2α. The reason for the reduced affinity of CK2α′ to CK2β and CK2β competitors is puzzling: both isoenzymes have identical amino acid compositions at their CK2β interfaces, but the β4β5 loop, a component of this interface, is conformationally less adaptable in CK2α′ than in CK2α due to intramolecular constraints. To release these constraints, we constructed a CK2α′ mutant that was equalized to CK2α at the backside of the β4β5 loop. Concerning thermostability, affinity to CK2β or CK2β competitors and 3D-structure next to the β4β5 loop, this CK2α′ mutant is more similar to CK2α than to its own wild-type, suggesting a critical role of the β4β5 loop adaptability for CK2β affinity.
- 1 March 2025
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 406 (3-4) , 101-115
Open AccessA CK2α′ mutant indicating why CK2α and CK2α′, the isoforms of the catalytic subunit of human protein kinase CK2, deviate in affinity to CK2β
Protein kinase CK2 (casein kinase 2) mainly exists as heterotetrameric holoenzyme with two catalytic subunits (CK2α or CK2α′) bound to a homodimer of non-catalytic subunits (CK2β). With CSNK2A1 and CSNK2A2, the human genome contains two paralogs encoding catalytic CK2 subunits. Both gene products, called CK2α and CK2α′, strongly interact with CK2β. An earlier report that CK2α′ has a lower CK2β affinity than CK2α is confirmed via isothermal titration calorimetry in this study. Furthermore, we show with a fluorescence-anisotropy assay that a CK2β-competitive peptide binds less strongly to CK2α′ than to CK2α. The reason for the reduced affinity of CK2α′ to CK2β and CK2β competitors is puzzling: both isoenzymes have identical amino acid compositions at their CK2β interfaces, but the β4β5 loop, a component of this interface, is conformationally less adaptable in CK2α′ than in CK2α due to intramolecular constraints. To release these constraints, we constructed a CK2α′ mutant that was equalized to CK2α at the backside of the β4β5 loop. Concerning thermostability, affinity to CK2β or CK2β competitors and 3D-structure next to the β4β5 loop, this CK2α′ mutant is more similar to CK2α than to its own wild-type, suggesting a critical role of the β4β5 loop adaptability for CK2β affinity.
- 7 February 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (3) , 831-840
Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer’s Disease
In this work, we designed, synthesized, and evaluated two types of multineurotargeting compounds using a pharmacophore merging strategy, aiming to develop potential treatments for Alzheimer's disease. We combined belinostat, an FDA-approved unselective histone deacetylase (HDAC) inhibitor, with the 5-substituted indole core of contilisant, known for its antioxidant and neuroprotective properties as well as its potent inhibitory activity against monoamine oxidases (MAOs), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Among these, compounds 8c (HDAC1, IC50 = 0.019 μM; HDAC6, IC50 = 0.040 μM; AChE, IC50 = 20.06 μM; BChE, IC50 = 17.10 μM; MAO-B, IC50 = 2.14 μM), and 9c (HDAC1, IC50 = 0.126 μM; HDAC6, IC50 = 0.020 μM; AChE, IC50 = 2.73 μM; BChE, IC50 = 4.03 μM; MAO-B, IC50 = 1.18 μM) emerged as the most promising candidates. These compounds warrant further investigation as potential treatments for Alzheimer's disease due to their unique inhibition profiles and favorable mode of inhibition.
- 7 February 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (3) , 831-840
Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer’s Disease
In this work, we designed, synthesized, and evaluated two types of multineurotargeting compounds using a pharmacophore merging strategy, aiming to develop potential treatments for Alzheimer's disease. We combined belinostat, an FDA-approved unselective histone deacetylase (HDAC) inhibitor, with the 5-substituted indole core of contilisant, known for its antioxidant and neuroprotective properties as well as its potent inhibitory activity against monoamine oxidases (MAOs), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). Among these, compounds 8c (HDAC1, IC50 = 0.019 μM; HDAC6, IC50 = 0.040 μM; AChE, IC50 = 20.06 μM; BChE, IC50 = 17.10 μM; MAO-B, IC50 = 2.14 μM), and 9c (HDAC1, IC50 = 0.126 μM; HDAC6, IC50 = 0.020 μM; AChE, IC50 = 2.73 μM; BChE, IC50 = 4.03 μM; MAO-B, IC50 = 1.18 μM) emerged as the most promising candidates. These compounds warrant further investigation as potential treatments for Alzheimer's disease due to their unique inhibition profiles and favorable mode of inhibition.
- Open Access
- 13 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1650
The Impact of Nε-Acryloyllysine Piperazides on the Conformational Dynamics of Transglutaminase 2
In addition to the classic functions of proteins, such as acting as a biocatalyst or binding partner, the conformational states of proteins and their remodeling upon stimulation need to be considered. A prominent example of a protein that undergoes comprehensive conformational remodeling is transglutaminase 2 (TGase 2), the distinct conformational states of which are closely related to particular functions. Its involvement in various pathophysiological processes, including fibrosis and cancer, motivates the development of theranostic agents, particularly based on inhibitors that are directed toward the transamidase activity. In this context, the ability of such inhibitors to control the conformational dynamics of TGase 2 emerges as an important parameter, and methods to assess this property are in great demand. Herein, we describe the application of the switchSENSE® principle to detect conformational changes caused by three irreversibly binding Nε-acryloyllysine piperazides, which are suitable radiotracer candidates of TGase 2. The switchSENSE® technique is based on DNA levers actuated by alternating electric fields. These levers are immobilized on gold electrodes with one end, and at the other end of the lever, the TGase 2 is covalently bound. A novel computational method is introduced for describing the resulting lever motion to quantify the extent of stimulated conformational TGase 2 changes. Moreover, as a complementary biophysical method, native polyacrylamide gel electrophoresis was performed under similar conditions to validate the results. Both methods prove the occurrence of an irreversible shift in the conformational equilibrium of TGase 2, caused by the binding of the three studied Nε-acryloyllysine piperazides.
- 13 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1650
Open AccessThe Impact of Nε-Acryloyllysine Piperazides on the Conformational Dynamics of Transglutaminase 2
In addition to the classic functions of proteins, such as acting as a biocatalyst or binding partner, the conformational states of proteins and their remodeling upon stimulation need to be considered. A prominent example of a protein that undergoes comprehensive conformational remodeling is transglutaminase 2 (TGase 2), the distinct conformational states of which are closely related to particular functions. Its involvement in various pathophysiological processes, including fibrosis and cancer, motivates the development of theranostic agents, particularly based on inhibitors that are directed toward the transamidase activity. In this context, the ability of such inhibitors to control the conformational dynamics of TGase 2 emerges as an important parameter, and methods to assess this property are in great demand. Herein, we describe the application of the switchSENSE® principle to detect conformational changes caused by three irreversibly binding Nε-acryloyllysine piperazides, which are suitable radiotracer candidates of TGase 2. The switchSENSE® technique is based on DNA levers actuated by alternating electric fields. These levers are immobilized on gold electrodes with one end, and at the other end of the lever, the TGase 2 is covalently bound. A novel computational method is introduced for describing the resulting lever motion to quantify the extent of stimulated conformational TGase 2 changes. Moreover, as a complementary biophysical method, native polyacrylamide gel electrophoresis was performed under similar conditions to validate the results. Both methods prove the occurrence of an irreversible shift in the conformational equilibrium of TGase 2, caused by the binding of the three studied Nε-acryloyllysine piperazides.
- Open Access
Facile Solvent-Free Mechanochemical Synthesis of UI3 and Lanthanoid Iodides
Lewis base-free lanthanoid (Ln) and actinoid (An) iodides are difficult to obtain, as standard protocols describe syntheses in solutions of donor solvents which are ultimately hard to remove. We have now established a mechanochemical approach towards the synthesis of Lewis base-free f-block metal iodides with excellent yields. In particular, we describe herein the synthesis of EuI2 as an example of a divalent lanthanoid iodide, of CeI3 as an example of a trivalent lanthanoid iodide, and of UI3 as the most important actinoid iodide. Each can be obtained in high yield with minimal work-up, presenting the most efficient and simple synthetic route to access these materials to date.
Open AccessFacile Solvent-Free Mechanochemical Synthesis of UI3 and Lanthanoid Iodides
Lewis base-free lanthanoid (Ln) and actinoid (An) iodides are difficult to obtain, as standard protocols describe syntheses in solutions of donor solvents which are ultimately hard to remove. We have now established a mechanochemical approach towards the synthesis of Lewis base-free f-block metal iodides with excellent yields. In particular, we describe herein the synthesis of EuI2 as an example of a divalent lanthanoid iodide, of CeI3 as an example of a trivalent lanthanoid iodide, and of UI3 as the most important actinoid iodide. Each can be obtained in high yield with minimal work-up, presenting the most efficient and simple synthetic route to access these materials to date.